therapeutics

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2026 17:33 ET  | Source: Tango Therapeutics Sub, Inc BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics,…

5 days ago

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

March 06, 2026 18:15 ET  | Source: Lisata Therapeutics, Inc. Each Lisata stockholder to receive $5.00 per share in cash…

6 days ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting…

1 week ago

Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing

Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”), a Delaware-incorporated, clinical-stage oncology biotechnology company, today announced…

1 week ago

Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit

LEHI, Utah, March 2, 2026 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies grounded in human biology, today…

1 week ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day…

2 weeks ago

Polaroid Therapeutics (PTx) Receives CE Mark for POLTX_Fiber: the first application of APT to launch a new standard in wound care

Introducing Antimicrobial Polymer Technology (APT™) in POLTX_Fiber™, a Class IIb advanced wound care dressing that does not contribute to antimicrobial…

2 weeks ago

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference

February 22, 2026 16:00 ET  | Source: Dyne Therapeutics, Inc. - Late-breaking poster to feature new positive cardiopulmonary function results…

3 weeks ago

Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates

2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed…

3 weeks ago

Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million

Proposed $1.0 Million Convertible Debenture and Warrant Financing and Concurrent Common Share Private Placement Up to $1.0 Million Intended to Support…

3 weeks ago